Statements (24)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
amphetamine
Hallucinogen |
| gptkbp:category |
recreational drug
|
| gptkbp:chemicalFormula |
C20H27NO3
|
| gptkbp:discoveredBy |
gptkb:David_E._Nichols
|
| gptkbp:effect |
psychedelic
hallucinogenic stimulant |
| gptkbp:firstSynthesized |
2010
|
| https://www.w3.org/2000/01/rdf-schema#label |
NBOMe-mescaline
|
| gptkbp:IUPACName |
2-(4-methoxy-3,5-dimethylphenyl)-N-[(2-methoxyphenyl)methyl]ethan-1-amine
|
| gptkbp:legalStatus |
unscheduled (varies by country)
|
| gptkbp:mechanismOfAction |
5-HT2A receptor agonist
|
| gptkbp:molecularWeight |
329.44 g/mol
|
| gptkbp:otherName |
2C-O-NBOMe
NBOMe-2C-O |
| gptkbp:relatedTo |
gptkb:NBOMe_series
mescaline |
| gptkbp:routeOfAdministration |
oral
sublingual buccal |
| gptkbp:structure |
substituted phenethylamine
|
| gptkbp:bfsParent |
gptkb:NBOMe_series
|
| gptkbp:bfsLayer |
7
|